Valneva
Valneva is a pharmaceutical company dedicated to the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical needs. It has successfully launched several vaccines, including IXIARO/JESPECT, DUKORAL, and IXCHIQ, primarily targeting travelers. Valneva is also involved in the development, manufacturing, and distribution of a COVID-19 vaccine, alongside a broad pipeline of vaccine candidates aimed at diseases such as Lyme disease and the chikungunya virus. The company focuses on advancing its research and development programs to create new vaccines, seeking to address public health challenges and generate future revenue through partnerships with other pharmaceutical firms. Additionally, Valneva offers technologies and services related to vaccine development and commercialization.
Crucell Sweden provides contract manufacturing services for vaccine companies in Sweden and internationally. The company manufactures biological bulk/API and finished products for clinical trials, as well as market supply.
BliNK Biomedical SAS specializes in the discovery and development of first or best-in-class antibody-based therapeutics for life threatening diseases such as cancer with a focus on immuno-oncology disease targets. Our lead program is a monoclonal antibody that targets an immune checkpoint to cause an immune switch that renders tumors susceptible to the body's immune system. Our other programs address a number of attractive, novel immuno-oncology and immune-checkpoint targets, some of which are unique to our approach. The antibodies that we are developing have the potential to be the next generation of anti-tumor therapeutics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.